Ikervis (Ciclosporin)

Ciclosporin binds cyclophilin inside ocular surface cells, forming a complex that inhibits calcineurin. This prevents activation of NF‑AT and reduces transcription of pro‑inflammatory cytokines such as interleukin‑2 and interferon‑γ. The resulting suppression of T‑cell activity diminishes ocular surface inflammation, leading to symptom relief in dry eye conditions.

The prescribed dose of Ikervis is determined by the treating ophthalmologist based on the severity of the condition and individual patient response. Typically, one drop is instilled into the affected eye(s) once daily, but the exact frequency and duration are set by the prescriber and may be adjusted during follow‑up visits.

The safety of ciclosporin ophthalmic emulsion in pregnancy and lactation has not been definitively established, and the product is classified with an unknown pregnancy category. Healthcare providers should weigh potential benefits against possible risks, and use Ikervis only if clearly needed. Breastfeeding mothers should consult their physician before initiating therapy.

To request Ikervis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Unlike artificial tears that provide symptomatic lubrication, Ikervis delivers an immunomodulatory effect by targeting T‑cell‑mediated inflammation. Compared with other calcineurin inhibitors such as Restasis (cyclosporine ophthalmic emulsion 0.05%), Ikervis contains a higher concentration (0.1%) and is formulated as an oil‑in‑water emulsion, which may improve ocular surface residence time and efficacy in moderate to severe cases.

Ikervis should be stored at room temperature, preferably below 25 °C, in its original packaging to protect it from light and moisture. Do not freeze the emulsion. Before use, gently invert the bottle to mix the contents, and avoid contaminating the dropper tip. Keep the container tightly closed when not in use.

Ikervis is applied as a single drop to the conjunctival sac of the affected eye(s) using the supplied dropper. The patient should wash their hands before instillation, tilt the head back, pull down the lower eyelid, and place the drop without touching the eye or lashes. The recommended frequency is set by the prescribing ophthalmologist.

Although uncommon, serious adverse events can include ocular infection, corneal ulceration and a rise in intra‑ocular pressure. Patients should be instructed to report any sudden pain, vision changes, persistent redness, or signs of infection promptly. Regular monitoring by an eye‑care professional helps detect and manage these risks early.

Ikervis is contraindicated in patients with known hypersensitivity to ciclosporin or any component of the emulsion. It should also be avoided in individuals with active ocular infections, uncontrolled glaucoma, or those who are currently receiving systemic immunosuppressive therapy without medical supervision. A qualified ophthalmologist must evaluate suitability before initiating treatment.